外交部:中國向「新冠肺炎疫苗實施計劃」提供1,000萬劑疫苗
外交部發言人汪文斌表示,中國已正式加入「新冠肺炎疫苗實施計劃」(COVAX),決定向實施計劃提供1,000萬劑疫苗,主要用於發展中國家急需。
世衛組織已開始審核中國疫苗的緊急使用授權,中國企業將繼續積極配合,希望世衛組織盡早完成這項工作。
汪文斌強調,中方希望國際社會有能力的國家都積極行動起來,以實際行動支持實施計劃,支持世衛組織工作,幫助發展中國家及時獲得疫苗,為國際社會早日戰勝疫情作出應有的貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.